Home › Head and Neck Cancer › Virginia
Head and Neck Cancer clinical trials in Virginia
15 studies for Head and Neck Cancer are looking for participants at sites in Virginia.
Cities in Virginia
Distance-Based Exercise to Preserve Function and Prevent Disability
- Bon Secours Memorial Regional Medical Center, Mechanicsville
- Bon Secours Saint Francis Medical Center, Midlothian
- Bon Secours Saint Mary's Hospital, Richmond
Recruiting
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT07059884FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC
- University of Virginia (Site#0134), Charlottesville
- Virginia Commonwealth University (VCU) Massey Cancer Center (Site #0129), Richmond
- Richmond Department of Veterans Affairs (Site #0138), Richmond
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Oct 29, 2026 · NCT06788990Ordastobart (INBRX-106) Add-on to Pembrolizumab in 1L HPV+ PD-L1+ R/M OPSCC (HexAgon-HN)
- VCU Massey Comprehensive Cancer Center, Richmond
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Oct 28, 2026 · NCT06295731A Study Evaluating Ficerafusp Alfa (BCA101) QW in Combination With Pembrolizumab vs Alternative Ficerafusp Alfa Dosing in 1L R or M HNSCC
- Site US073, Roanoke
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 13, 2026 · NCT07807163Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
- NEXT, Fairfax
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 13, 2026 · NCT06993844The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- Virginia Cancer Specialists, Fairfax
RecruitingPhase 1/2
Ages 12 and older · All sexes · Updated Oct 2, 2026 · NCT04585750A Phase 1, First-in-Human (FIH), Open-Label, Dose-Escalation and Dose Expansion Study of the Peptide Drug Conjugate (PDC), TS-104, as a Monotherapy in Subjects With Select Advanced Solid Tumors
- Site 04, Fairfax
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 30, 2026 · NCT07814248A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors
- ALX Center 2, Fairfax
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 30, 2026 · NCT07085091Atorvastatin to Reduce Cisplatin-Induced Hearing Loss Among Individuals With Head and Neck Cancer
- Inova Schar Cancer Center, Fairfax
RecruitingPhase 2
Ages 18 to 100 · All sexes · Updated Sep 2, 2026 · NCT04915183First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
- USO-Virginia Cancer Specialists, PC, Fairfax
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Jul 7, 2026 · NCT05768139A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma
- GSK Investigational Site, Fredericksburg
- GSK Investigational Site, Wytheville
RecruitingPhase 3
Ages 18 and older · All sexes · Updated May 26, 2026 · NCT06256588Velopharyngeal Dysfunction in Head & Neck Cancer Patients, Pilot Study
- University of Virginia, Charlottesville
Recruiting
Ages 18 and older · All sexes · Updated Apr 28, 2026 · NCT07264036Stereotactic MRI-guided Focused Ultrasound Mesencephalotomy
- University of Virginia, Charlottesville
Recruiting
Ages 18 to 85 · All sexes · Updated Feb 12, 2026 · NCT07405645HPV DNA-Guided Radiotherapy De-intensification of Head and Neck Squamous Cell Carcinoma
- University of Virginia, Charlottesville
- Eastern Virginia Medical School, Norfolk
- Bon Secours, Richmond
- and 1 more
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Feb 5, 2026 · NCT05962242SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Charlottesville
RecruitingObservational study
All ages · All sexes · Updated Oct 28, 2025 · NCT03452774From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.